18525027

Source:http://linkedlifedata.com/resource/pubmed/id/18525027

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0012634, umls-concept:C0015980, umls-concept:C0026769, umls-concept:C0286651, umls-concept:C0441655, umls-concept:C0442805
pubmed:issue	18
pubmed:dateCreated	2008-10-28
pubmed:abstractText	To explore whether high-dose atorvastatin can be administered safely to persons with relapsing-remitting multiple sclerosis (MS) taking thrice weekly, 44 microg dose subcutaneous interferon beta-1a.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18525027-18955682, http://linkedlifedata.com/resource/pubmed/commentcorrection/18525027-19487658, http://linkedlifedata.com/resource/pubmed/commentcorrection/18525027-19786703
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0401060
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol, http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA..., http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-beta, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/atorvastatin
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	1526-632X
pubmed:author	pubmed-author:AltafullahII, pubmed-author:BirnbaumGG, pubmed-author:CreaFF, pubmed-author:ReddyA LAL, pubmed-author:ZinserMM
pubmed:issnType	Electronic
pubmed:day	28
pubmed:volume	71
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1390-5
pubmed:dateRevised	2009-9-29
pubmed:meshHeading	pubmed-meshheading:18525027-Adult, pubmed-meshheading:18525027-Analysis of Variance, pubmed-meshheading:18525027-Chi-Square Distribution, pubmed-meshheading:18525027-Cholesterol, pubmed-meshheading:18525027-Dose-Response Relationship, Drug, pubmed-meshheading:18525027-Double-Blind Method, pubmed-meshheading:18525027-Drug Therapy, Combination, pubmed-meshheading:18525027-Female, pubmed-meshheading:18525027-Follow-Up Studies, pubmed-meshheading:18525027-Heptanoic Acids, pubmed-meshheading:18525027-Humans, pubmed-meshheading:18525027-Hydroxymethylglutaryl-CoA Reductase Inhibitors, pubmed-meshheading:18525027-Immunologic Factors, pubmed-meshheading:18525027-Interferon-beta, pubmed-meshheading:18525027-Magnetic Resonance Imaging, pubmed-meshheading:18525027-Male, pubmed-meshheading:18525027-Middle Aged, pubmed-meshheading:18525027-Multiple Sclerosis, Relapsing-Remitting, pubmed-meshheading:18525027-Neurologic Examination, pubmed-meshheading:18525027-Pyrroles, pubmed-meshheading:18525027-Survival Analysis
pubmed:year	2008
pubmed:articleTitle	Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
pubmed:affiliation	MS Treatment and Research Center, Minneapolis Clinic of Neurology, 4225 Golden Valley Road, Golden Valley, MN 55422, USA. birnb001@tc.umn.edu
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't